CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2014 MASCC/ISOO International Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Keefe on the Role of Supportive Care in Personalized Medicine
Dr. Rapoport on Rolapitant for the Prevention of CINV
Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of Malnutrition
Oncology Conference Articles
Aprepitant Yields Significant Benefits for the Prevention of CINV in Children
Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.
Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC
Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.
Two Phase III Trials Find Rolapitant Effective, Well-Tolerated for Preventing CINV
A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.
Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINV
Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.
Netupitant-Palonosetron Combination Shows Continued Superiority Over Palonosetron for CINV
A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.
Aprepitant- and Metoclopramide-Based Regimens Demonstrate Similar Efficacy in Preventing Delayed Cisplatin-Induced Emesis
For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.
FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More
Neoadjuvant Immunotherapy Emerges as a New Frontier
Master of the Whipple Gave Hope, Extended Lives
FDA Approves Nivolumab for Small Cell Lung Cancer
FDA Grants Full Approval to Pembrolizumab Plus Chemo for NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.